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and its association with a poor prognosis, the epidermal
growth factor receptor (EGFR) is used as a therapeutic target
in clinical routine and in clinical trials. Two major classes of
inhibitors are used: anti-EGFR antibodies and EGFR tyrosine
kinase inhibitors (TKIs). On simultaneous application of the
anti-EGFR antibody cetuximab with radiotherapy in head
and neck squamous-cell carcinoma (HNSCC) patients, an
improvement in locoregional tumour control and survival
has been shown as compared with radiotherapy alone, lead-
ing to the approval of this drug as the first molecular targeted
agent in a curative radio-oncological setting. However, so far
there is no hint of a superiority of this combination over
simultaneous cisplatin-based radiochemotherapy; thus, both
treatments are used today as alternative schedules.
While it is evident from preclinical as well as from clinical
data that a major heterogeneity exists among the responses
of individual patients to the combined treatment, apart from
skin reactions under cetuximab treatment, there is so far no
validated biomarker predicting response to cetuximab-based
combined treatment, nor to cisplatin-based radiochemother-
apy. Establishing predictive biomarkers would highly increase
efficacy of the treatment due to the positive selection of pa-
tients. Some conclusions can currently be drawn from trans-
lationally oriented studies: at least for HNSCCs (others have
not been well investigated), cetuximab application during
radiotherapy improves locoregional tumour control in many
but not all individual tumours, with individually impressive
responses. For EGFR–TKI all local tumour control studies have
been negative so far, whereas palliative effects have been
shown in most HNSCCs. A promising candidate biomarkerfor the effect of combined radiotherapy and cetuximab in
HNSCC is genetic EGFR over-expression measured by the fluo-
rescence in situ hybridization (FISH) test. This marker has to
be further validated in clinical settings, as well as for other tu-
mour entities or combination schedules. Because of interac-
tions between the treatment modalities, such biomarkers
can be different between single-modality and combined-
modality treatments.
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